Literature DB >> 18274029

The incidence of phlebitis with intravenous amiodarone at guideline dose recommendations.

Ahmad M Slim1, Jason E Roth, Benjamin Duffy, Sheri Y N Boyd, Bernard J Rubal.   

Abstract

Postoperative atrial fibrillation following cardiothoracic surgery is common and frequently managed with intravenous (IV) amiodarone. Phlebitis is the most common complication with peripheral infusion of this agent. Current practice guidelines for peripheral IV administration of <2 mg/mL amiodarone were established to reduce the risk of phlebitis. The present study examines the incidence of phlebitis in a postoperative patient population given current dose recommendations. A total of 273 patient charts were reviewed. The incidence of phlebitis in patients given IV amiodarone (n = 36) was 13.9% (95% confidence interval, 2.6-25.2%; p = 0.001). Logistic regression analysis with backward elimination of other therapeutic risk factors suggests that the odds ratio for phlebitis using current dose regimens without IV filters is 19-fold greater than baseline risk in this population. Phlebitis remains a significant complication associated with peripheral infusion of amiodarone within recommended dosing limits.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18274029

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  2 in total

1.  The effects of sesame oil on the prevention of amiodarone-induced phlebitis.

Authors:  Masoumeh Bagheri-Nesami; Seyed Afshin Shorofi; Seyedeh Zahra Hashemi-Karoie; Alireza Khalilian
Journal:  Iran J Nurs Midwifery Res       Date:  2015 May-Jun

2.  Study on Protection of Human Umbilical Vein Endothelial Cells from Amiodarone-Induced Damage by Intermedin through Activation of Wnt/β-Catenin Signaling Pathway.

Authors:  Yanhong Wang; Juanjuan Wang; Jia Yang; Jing Kang; Fuping Xue; Sijia Chang; He Ji; Haojing Zang; Xiaoshuang Zhou; Guiqin Wang; Weiping Fan; Xianyan Yan; Jinli Guo; Xiaojun Ren; Jihua Tian
Journal:  Oxid Med Cell Longev       Date:  2021-08-14       Impact factor: 6.543

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.